Medpace is a founder-led clinical contract research organization whose mid-year print reopened a debate the first quarter had nearly closed. After a cancellation-heavy start that dropped net book-to-bill below one and sent the stock sharply lower, the second quarter produced record net awards and a guidance raise. The question is no longer whether demand vanished. It is whether a 17 percent revenue sprint is consuming backlog faster than awards can rebuild it.
Oncology took more than half of second-quarter bookings as large metabolic programs faded, which is the mix shift founder August Troendle described on the July call. Net awards reached $796 million. That restored a book-to-bill above one after a first-quarter print below one. Ending backlog still grew only about 5 percent. Revenue still advanced 17 percent. Conversion of beginning backlog ran at 24 percent. Troendle called that pace high versus the company's own history. The cushion under next year's revenue is thinner even as the bookings scare eased.
The company lifted full-year revenue and earnings forecasts and spent $295 million buying back stock into the first-quarter air pocket. A securities class action filed in April still alleges that last year's book-to-bill commentary was too optimistic. Does a single rebound quarter prove the cancellation spike was a one-period event, or does slow backlog growth show the model is running hotter than it can refill?